Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.5820
-0.0289-4.73%
Last update: May 15, 12:25 PM
Lexaria Bioscience Corp Analyst Ratings
LEXXNASDAQ
Lexaria Bioscience Analyst Ratings and Price Targets | NASDAQ:LEXX | Benzinga
Lexaria Bioscience Corp has a consensus price target of $6.75 based on the ratings of 2 analysts. The high is $12 issued by Maxim Group on March 5, 2024. The low is $1.5 issued by HC Wainwright & Co. on December 26, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on December 26, 2025, July 29, 2025, and July 1, 2025, respectively. With an average price target of $3.5 between HC Wainwright & Co., there's an implied 501.37% upside for Lexaria Bioscience Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Maxim Group
1calculated from analyst ratings
Analyst Ratings for Lexaria Bioscience
Loading calendar...
FAQ
What is the target price for Lexaria Bioscience (LEXX) stock?
The latest price target for Lexaria Bioscience (NASDAQ:LEXX) was reported by HC Wainwright & Co. on December 26, 2025. The analyst firm set a price target for $1.50 expecting LEXX to rise to within 12 months (a possible 157.73% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lexaria Bioscience (LEXX)?
The latest analyst rating for Lexaria Bioscience (NASDAQ:LEXX) was provided by HC Wainwright & Co., and Lexaria Bioscience maintained their buy rating.
When was the last upgrade for Lexaria Bioscience (LEXX)?
There is no last upgrade for Lexaria Bioscience
When was the last downgrade for Lexaria Bioscience (LEXX)?
There is no last downgrade for Lexaria Bioscience.
When is the next analyst rating going to be posted or updated for Lexaria Bioscience (LEXX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lexaria Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lexaria Bioscience was filed on December 26, 2025 so you should expect the next rating to be made available sometime around December 26, 2026.
Is the Analyst Rating Lexaria Bioscience (LEXX) correct?
While ratings are subjective and will change, the latest Lexaria Bioscience (LEXX) rating was a maintained with a price target of $4.00 to $1.50. The current price Lexaria Bioscience (LEXX) is trading at is $0.58, which is out of the analyst’s predicted range.
